{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:40:33Z","timestamp":1773708033546,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2018,5,10]],"date-time":"2018-05-10T00:00:00Z","timestamp":1525910400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Experimental Dermatology"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>When applied topically, oxymetazoline and brimonidine reduce the persistent facial erythema of rosacea; this effect is mediated by cutaneous vasoconstriction induced by postsynaptic activation of \u03b1\u2010adrenoceptors. We investigated the \u03b1\u2010adrenergic pharmacology of oxymetazoline and brimonidine. Functional activity on \u03b1\u2010adrenoceptors was evaluated in vitro in HEK293 cells stably expressing single receptor subtypes using a fluorometric imaging plate reader Ca<jats:sup>2+<\/jats:sup>influx assay. Oxymetazoline was an \u03b1<jats:sub>1<\/jats:sub>\u2010adrenoceptor agonist with partial \u03b1<jats:sub>2<\/jats:sub>\u2010adrenoceptor activity, whereas brimonidine was a highly selective full \u03b1<jats:sub>2<\/jats:sub>\u2010adrenoceptor agonist. In vivo pharmacology was investigated in a mouse model of ultraviolet B light (UVB)\u2010induced skin erythema. To selectively inhibit \u03b1\u2010adrenoceptor subtypes, mice were injected with prazosin (an \u03b1<jats:sub>1<\/jats:sub>\u2010selective antagonist) or rauwolscine (an \u03b1<jats:sub>2<\/jats:sub>\u2010selective antagonist) following UVB exposure. Oxymetazoline cream 1.0%, brimonidine gel 0.33% or vehicle control was applied topically, and erythema was measured using a chromameter. Oxymetazoline and brimonidine reduced UVB\u2013induced erythema compared with vehicle control (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a0.01). The effect of oxymetazoline was impaired in prazosin\u2010pretreated but not rauwolscine\u2010pretreated mice. Conversely, the effect of brimonidine was impaired in rauwolscine\u2010pretreated but not prazosin\u2010pretreated mice. These data suggest that while oxymetazoline and brimonidine produce cutaneous vasoconstriction, they do so through different \u03b1\u2010adrenergic mechanisms, with oxymetazoline primarily acting via \u03b1<jats:sub>1<\/jats:sub>\u2010adrenoceptors and brimonidine acting via \u03b1<jats:sub>2<\/jats:sub>\u2010adrenoceptors.<\/jats:p>","DOI":"10.1111\/exd.13557","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T03:24:41Z","timestamp":1523417081000},"page":"763-768","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Reduction in ultraviolet B light\u2013induced erythema by oxymetazoline and brimonidine is mediated by different \u03b1\u2010adrenoceptors"],"prefix":"10.1111","volume":"27","author":[{"given":"Edward","family":"Hsia","sequence":"first","affiliation":[{"name":"Research Allergan plc Irvine CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingting","family":"Tian","sequence":"additional","affiliation":[{"name":"Research Allergan plc Irvine CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gil","sequence":"additional","affiliation":[{"name":"Research Allergan plc Irvine CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,5,10]]},"reference":[{"key":"e_1_2_8_2_1","volume-title":"Rosacea Review","author":"Drake L.","year":"2010"},{"key":"e_1_2_8_3_1","first-page":"725","volume":"11","author":"Baldwin H. E.","year":"2012","journal-title":"J. Drugs Dermatol."},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.05.036"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.06.009"},{"key":"e_1_2_8_6_1","first-page":"26","volume":"5","author":"Del Rosso J. Q.","year":"2012","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0031-6997(24)01495-9","volume":"53","author":"Guimaraes S.","year":"2001","journal-title":"Pharmacol. Rev."},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.2741\/S105"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.05.005"},{"key":"e_1_2_8_10_1","first-page":"H1197","volume":"263","author":"Freedman R. R.","year":"1992","journal-title":"Am. J. Physiol."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.0000128407.45014.58"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1566-0702(02)00046-2"},{"key":"e_1_2_8_13_1","unstructured":"Rhofade [package insert] Allergan Irvine CA 2017."},{"key":"e_1_2_8_14_1","unstructured":"Mirvaso [package insert] Galderma Laboratories Fort Worth TX 2016."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0022-202x.2001.01514.x"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.04.045"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12666001"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.04.002"},{"key":"e_1_2_8_19_1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0022-3565(24)37841-3","volume":"287","author":"Kukkonen J. P.","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00306-4"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(97)00631-X"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.3746\/pnf.2012.17.4.245"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-1097.2007.00288.x"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6882-14-281"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.188"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051725"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000017904"},{"key":"e_1_2_8_28_1","unstructured":"L. H.Kircik J.DuBois Z. D.Draelos P.Werschler K.Grande F. E.Cook\u2010Bolden D. R.Berk G.Ahluwalia Fall Clinical Dermatology Conference Las Vegas NV 2016."},{"key":"e_1_2_8_29_1","unstructured":"L.Baumann D. J.Goldberg L.Stein\u2010Gold E. A.Tanghetti T.Lain J.Kaufman D. R.Berk G.Ahluwalia Fall Clinical Dermatology Conference Las Vegas NV 2016."},{"key":"e_1_2_8_30_1","first-page":"650","volume":"12","author":"Fowler J.","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"e_1_2_8_31_1","first-page":"56","volume":"13","author":"Moore A.","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"e_1_2_8_32_1","unstructured":"L.Stein\u2010Gold L. H.Kircik Z. D.Draelos P.Werschler J.DuBois E.Lain L.Baumann D. J.Goldberg J.Kaufman E. A.Tanghetti E.Weng D. R.Berk G.Ahluwalia Annual Meeting of the American Academy of Dermatology Orlando FL 2017."},{"key":"e_1_2_8_33_1","unstructured":"Z. D.Draelos M. H.Gold R. A.Weiss L.Baumann S. K.Grekin D.Mraz Robinson S. E.Kempers D. R.Berk G.Ahluwalia Annual Meeting of the American Academy of Dermatology Orlando FL 2017."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0404-8"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.4049\/jimmunol.145.5.1430","volume":"145","author":"Spengler R. N.","year":"1990","journal-title":"J. Immunol."}],"container-title":["Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fexd.13557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/exd.13557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T15:37:34Z","timestamp":1751557054000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/exd.13557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,10]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["10.1111\/exd.13557"],"URL":"https:\/\/doi.org\/10.1111\/exd.13557","archive":["Portico"],"relation":{},"ISSN":["0906-6705","1600-0625"],"issn-type":[{"value":"0906-6705","type":"print"},{"value":"1600-0625","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,10]]},"assertion":[{"value":"2018-04-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-10","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}